Related Experiment Video
Updated: May 7, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
Published on: October 7, 2009
Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a)
Christof Wedemeyer1, Martin Peters1, Graham Jones2,3
1Patient Solutions & Services, Novartis Pharma AG, Basel, Switzerland.
Abstract:
Despite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening. Herein we outline how digital tools framed around motivational models (COM-B and SEM), might help increase likelihood of patients seeking Lp(a) testing as part of their managed care. Furthermore, we highlight how recent trends in prescription of GLP-1 receptor antagonists are serving to motivate patients to manage biomarkers related to T2D and obesity, which are also relevant in cardiovascular disease. Capitalizing on this trend to stimulate interest in Lp(a) management could have near term consequence, and with disease modifying therapies in development ultimately improve outcomes in cardiovascular disease.
More Related Videos
Related Concept Videos
Health Literacy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management

